Sotagliflozin is a prescription medication used to help improve blood sugar (glucose) control in adults with type 1 diabetes or type 2 diabetes. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, meaning it helps control the amount of sugar that is reabsorbed by the kidneys. It works by blocking the action of the SGLT2 protein, which is responsible for allowing glucose to be reabsorbed back into the bloodstream. This allows more glucose to be eliminated through the urine, resulting in lower blood sugar levels. Sotagliflozin is taken as a once-daily tablet, and can be used in combination with other diabetes medications.
Sotagliflozin is a medication used to target specific health issues, primarily related to blood sugar control and heart health. Here's a breakdown of its key features:
What it is:
- Sotagliflozin is a medication sold under the brand name Inpefa, among others.
- It falls under the drug class called SGLT1/2 inhibitor, specifically a dual inhibitor.
How it works:
- Sotagliflozin works by blocking the reabsorption of sugar (glucose) by the kidneys. This forces the body to eliminate excess sugar through urine, lowering blood sugar levels.
- It has a dual action because it inhibits both SGLT1 and SGLT2 receptors. SGLT1 is found in the intestines and SGLT2 is in the kidneys. This dual effect can provide more comprehensive blood sugar control.
Primary uses:
- In the US: Sotagliflozin is approved to reduce the risk of cardiovascular death and heart failure in adults with specific risk factors. These include:
- Heart failure
- Type 2 diabetes mellitus
- Chronic kidney disease
- Other cardiovascular risk factors
- In the EU: Previously approved for type 1 diabetes mellitus (T1DM) but withdrawn due to commercial reasons (March 2022).
Important to know:
- Sotagliflozin is typically used alongside other medications for diabetes or heart failure management.
- It's a prescription medication and requires a doctor's evaluation to determine if it's suitable for your condition.
- There can be side effects associated with Sotagliflozin, so it's important to discuss these with your doctor before using it. Some common side effects include genital infections, diabetic ketoacidosis (DKA), diarrhea, and urinary tract infections.
Here are some additional points to consider:
- Sotagliflozin is a relatively new medication (FDA approved May 2023).
- It's not a first-line treatment for all conditions and may not be suitable for everyone.